Clinical Trials Logo

Pulmonary Tuberculosis clinical trials

View clinical trials related to Pulmonary Tuberculosis.

Filter by:

NCT ID: NCT02053129 Completed - Clinical trials for Pulmonary Tuberculosis

Evaluation of PTB Screening in ANC in Lusaka, Zambia

Start date: November 2011
Phase: N/A
Study type: Interventional

This is a pilot pulmonary TB screening program done in three antenatal care clinics in Lusaka, Zambia to determine the prevalence of culture-confirmed pulmonary tuberculosis and to determine the sensitivity and specificity of symptom-based TB screening.

NCT ID: NCT01927159 Completed - Clinical trials for Pulmonary Tuberculosis

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.

NCT ID: NCT01691534 Active, not recruiting - Clinical trials for Pulmonary Tuberculosis

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

NC-003
Start date: September 2012
Phase: Phase 2
Study type: Interventional

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 plus PA-824 plus Pyrazinamide plus Clofazimine, TMC207 plus PA-824 plus Pyrazinamide, TMC207 plus PA-824 plus Clofazimine alone, TMC207 plus Pyrazinamide plus Clofazimine, Pyrazinamide alone, Clofazimine alone, and standard first line TB treatment as per South African TB Guidelines (Rifafour e-275) as determined by the rate of change of log CFU per ml sputum over the time period Day 0-14 in participants with smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.

NCT ID: NCT01618422 Completed - Clinical trials for Pulmonary Tuberculosis

Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou

Start date: March 2009
Phase: N/A
Study type: Interventional

This is a prospective, randomized, parallel, controlled study comparing the efficacy and outcomes in the retreatment of pulmonary Tuberculosis (TB) in Guangzhou in a group using pretreatment susceptibility tests in selection of chemotherapy regimens and that in another group without using pretreatment susceptibility test results. The investigators hypothesize that selecting drug treatment on the basis of known susceptibility tests would lead to improved outcome compared with empiric treatment.

NCT ID: NCT01599897 Completed - Clinical trials for Pulmonary Tuberculosis

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis. The vaccine, identified as ID93 + GLA-SE, consists of the recombinant four-antigen Mycobacterium tuberculosis recombinant protein ID93 together with the adjuvant GLA-SE.

NCT ID: NCT01580007 Completed - Clinical trials for Pulmonary Tuberculosis

Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

Vitamin D exerts its effects via the Vitamin D Receptor (VDR) present in activated macrophages and induces expression and release of the cathelicidin, LL-37, a human antimicrobial peptide involved in killing of MTB. We aimed to investigate whether treatment of newly diagnosed pulmonary TB patients for 2 months with adjunctive PBA and vitamin D (Cholecalciferol) in combination with standard DOTS therapy (i) can improve response to standard short course TB therapy towards a rapid recovery; (ii) can induce expression of LL-37 in macrophages; (iii) can enhance killing capacity of macrophages isolated from TB patients infected in vitro with MTB; and (iv) does not evoke any adverse effects.

NCT ID: NCT01503099 Recruiting - Crohn's Disease Clinical Trials

Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease

Start date: October 2009
Phase: N/A
Study type: Observational

One aims to devise a method for the screening and differentiation of intestinal tuberculosis and Crohn's Disease. Additionally, one aims to detect and survey multidrug resistant TB.

NCT ID: NCT01498419 Completed - Clinical trials for Pulmonary Tuberculosis

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the mycobactericidal activity of the moxifloxacin plus PA-824 plus pyrazinamide regimen after 8 weeks of treatment.

NCT ID: NCT01379066 Completed - Clinical trials for Pulmonary Tuberculosis

Tuberculosis Volatile Organic Compounds

TBVOC
Start date: August 2009
Phase: N/A
Study type: Observational

The Pulmonary Colonization Test is a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of mycobacterial organisms in the lower respiratory tract. It consists of: - A breath collection apparatus for collection of volatile organic compounds in breath onto a sorbent trap and Tedlar bag, as well as for the collection of a separate sample of room air. - Analysis of the volatile organic compounds in breath and room air by short acoustic wave/gas chromatography. - Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of lower respiratory tract colonization and infection. - Analysis of the volatile organic compounds in sputum culture by short acoustic wave/gas chromatography. This study will test the hypothesis that the investigators can identify the presence of mycobacteria in an individual by sampling the breath of patients with active tuberculosis and by sampling "head space" above culture media of sputum provided. This study will test the hypotheses: - that the investigators can identify positive cultures for mycobacterium tuberculosis through sampling of the headspace above the cultures prior to standard laboratory culture identification - that the investigators can identify control of tuberculosis by sampling exhaled breath

NCT ID: NCT01242592 Completed - Clinical trials for Pulmonary Tuberculosis

Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis

Start date: February 2005
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the effect of homeopathy as an adjuvant to Anti tuberculosis treatment on sputum conversion, hematological, clinical sign and symptoms of relapsed Pulmonary TB.